SecBot SecBot
8-K ·Filed Nov 5, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 9h ago SEC0001628280-26-071129
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor the tender offer conditions and regulatory approvals for the Viatris acquisition. The absence of Q3 earnings removes a near-term catalyst, and the stock will trade primarily on deal completion probability and timeline.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$36.43
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.08%
T+5 · $36.46 · next T+20 in 20d
Vs SPY
−2.51%
α at T+5
Latest observation
+1.75%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $36.43entry
  2. T+1 · 8d ago +0.08%α −2.28% · $36.46
  3. T+5 · 4d ago +0.08%α −2.51% · $36.46
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences will not issue its Q3 2026 earnings release or hold a conference call due to the pending acquisition by Viatris at $36.50 per share. The company has also withdrawn its 2026 financial guidance and will not provide updates during the pendency of the tender offer and merger.

Key Facts

  • On October 8, 2026, Pacira entered into a merger agreement with Viatris Inc.
  • On October 30, 2026, Viatris commenced a tender offer to purchase all Pacira shares for $36.50 per share in cash.
  • Pacira will not issue an earnings release for the quarter ended September 30, 2026.
  • Pacira is withdrawing its previously issued 2026 financial guidance.
  • The merger will be effected under Section 251(h) of the DGCL following consummation of the tender offer.

Financial Impact

No financial results disclosed; acquisition consideration is $36.50 per share in cash.

revenueearningsguidance

Risk Factors

  • The tender offer is subject to conditions including a minimum condition and regulatory approvals.
  • A competing offer could emerge, though none is mentioned.
  • If the deal fails, the lack of recent financial guidance and earnings creates uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-071129
Document: 0001628280-26-071129-index-headers.html0001628280-26-071129
Document: 0001628280-26-071129-index.html0001628280-26-071129
Document: 0001628280-26-071129.txt0001628280-26-071129

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026